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Background
Heme oxygenase-1 (HO-1) is a highly inducible enzyme
that metabolizes heme to generate equimolar amounts
of carbon monoxide (CO), biliverdin, and ferrous iron.
Subsequently, biliverdin is metabolized to the potent
antioxidant bilirubin by biliverdin reductase. Compelling
experimental evidence indicates that HO-1 and its end
products protect against the development of vascular
d y s f u n c t i o ni na n i m a lm o d e l s atherosclerosis, post-
angioplasty restenosis, vein graft stenosis, thrombosis,
myocardial infarction, and hypertension.
Results
Studies from our laboratory and others have identified
HO-1 as a critical regulator of vascular remodeling fol-
lowing arterial injury. Pharmacological induction or
gene delivery of HO-1 suppresses neointima formation
following arterial injury while HO-1 deletion exacerbates
lesion development. Similarly, local or systemic adminis-
tration of CO inhibits intimal thickening following arter-
ial injury. Studies in cultured vascular smooth muscle
cells (SMCs) reveal that overexpression of HO-1 or exo-
genously applied CO blocks SMC proliferation. The
anti-proliferative action of CO is dependent on the acti-
vation of soluble guanylate cyclase and is associated
with the arrest of SMCs in the G0/G1 phase of the cell
cycle. Interestingly, the soluble guanylate cyclase stimu-
lator YC-1 potentiates the anti-proliferative actions of
CO in cultured SMCs and uniquely stimulates the pro-
duction of CO by inducing HO-1 gene expression, pro-
viding a novel mechanism by which this agent is able to
amplify cGMP production. YC-1 also suppresses neoin-
tima formation, and this is associated with an increase
in cGMP levels in injured arteries. Finally, HO-1 defi-
ciency impairs endothelium-dependent vasorelaxation
and alters vasorelaxation responses to soluble guanylate
cyclase stimulators and activators. The alteration in
vasoreactivity in HO-1-deficient animals is accompanied
by a pronounced decline in soluble guanylate cyclase
expression.
Conclusion
Collectively, these findings demonstrate that HO-1 eli-
cits important protective actions in the vasculature by
stimulating soluble guanylate cyclase activity and preser-
ving soluble guanylate cyclase expression.
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